Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
暂无分享,去创建一个
Ayalew Tefferi | Z. Estrov | H. Kantarjian | S. Verstovsek | J. Fridman | R. Mesa | A. Tefferi | Deborah A. Thomas | A. Pardanani | K. Vaddi | Hagop Kantarjian | R. Levy | Srdan Verstovsek | Zeev Estrov | Jordan S Fridman | Deborah A Thomas | Ruben A Mesa | Kris Vaddi | Richard Levy | Animesh D Pardanani | Jorge Cortes-Franco | Edward C Bradley | Susan Erickson-Viitanen | J. Cortes-Franco | S. Erickson‐Viitanen | E. Bradley | D. Thomas
[1] H. Kantarjian,et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.
[2] H. Kantarjian,et al. Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Sloan,et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. , 2009, Leukemia research.
[4] T. Barbui,et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. , 2009, Blood.
[5] D. Hwang,et al. Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[7] S. Verstovsek. Therapeutic potential of JAK2 inhibitors. , 2009, Hematology. American Society of Hematology. Education Program.
[8] B. Gajkowska,et al. Crossroads of cytokine signaling--the chase to stop muscle cachexia. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[9] G. Barosi,et al. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders , 2008, Leukemia.
[10] R. Mesa,et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.
[11] Paola Guglielmelli,et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.
[12] J. Spivak,et al. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. , 2007, Experimental hematology.
[13] J. Sloan,et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) , 2007, Cancer.
[14] H. Deeg,et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.
[15] A. Tefferi. New insights into the pathogenesis and drug treatment of myelofibrosis , 2006, Current opinion in hematology.
[16] D. Steensma,et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .
[17] E. Hatzimichael,et al. Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseases , 2005, British Journal of Haematology.
[18] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[19] D. Steensma,et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.
[20] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[21] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[22] R. Kurzrock. The role of cytokines in cancer‐related fatigue , 2001, Cancer.
[23] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[24] P. Morel,et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.
[25] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.